Author:
Noda Sonomi,Harai Nozomi,Komai Saki,Inukai Takahiko,Watanabe Tomomi,Hosokawa Tadatsugu,Antoku Airi,Muroi Yuko,Hayashida Ryosuke,Okuma Hideyuki,Suzuki Yuichiro,Tsuchiya Kyoichiro
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference10 articles.
1. Takaike H, Uchigata Y, Iwamoto Y, Imagawa A, Iwahashi H, Kanatsuka A, Kawakaki E, Kobayashi T, Shimada A, Shimizu I, Maruyama T, Hanafusa T, Makino H. Nationwide survey to compare the prevalence of transient elevation of liver transaminase during treatment of diabetic ketosis or ketoacidosis in new-onset acute and fulminant type 1 diabetes mellitus. Ann Med. 2008;40(5):395–400.
2. Takaike H, Uchigata Y, Iwasaki N, Iwamoto Y. Transient elevation of liver transaminase after starting insulin therapy for diabetic ketosis or ketoacidosis in newly diagnosed type 1 diabetes mellitus. Diabetes Res Clin Pract. 2004;64:27–32.
3. Kwong TC, Sparks JD, Cianci JF, Sparks CE. Inhibition of apolipoprotein B net synthesis and secretion from cultured rat hepatocytes by the calcium-channel blocker diltiazem. Europe PMC. 1989;263(2):411–5.
4. Sparks JD, Zolfaghari R, Sparks CE, Smith HC, Fisher EA. Impaired hepatic apolipoprotein B and E translation in streptozotocin diabetic rats. J Clin Invest. 1992;89(5):1418–30.
5. Eric F, Elizabeth L, Roger SM. Apolipoprotein B100 quality control and the regulation of hepatic very low density lipoprotein secretion. J Biomed Res. 2014;28(3):178–93.